|
Market Closed -
Other stock markets
|
After hours 04:00:00 | |||
| 24.17 USD | -0.33% |
|
24.20 | +0.10% |
| 07-11 | Health Care Down on Rotation Back to Tech - Health Care Roundup | DJ |
| 07-10 | Merck, Pfizer, Astellas Bladder Cancer Treatment Approved by FDA | DJ |
Evolution of the Average Target: Pfizer Inc.
Evolution of the Target Price: Pfizer Inc.
Changes in Analyst Recommendations: Pfizer Inc.
| Consensus | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Objective/dr gap | ||
|---|---|---|---|---|---|---|
 | +19.74% | |||||
| +4.61% | |||||
| +0.79% | |||||
| +5.48% | |||||
| +6.72% | |||||
| -0.25% | |||||
| +25.02% | |||||
| -1.66% | |||||
| -2.13% | |||||
| +21.93% | |||||
| Average | +8.03% | |||||
| Weighted average by Cap. | +5.96% |
Analysts' Consensus
Analyst Consensus Detail
Consensus revision (last 18 months)
Analysts covering the company
| BofA Securities | |
| RBC | Trung Huynh |
| JPMorgan Chase | |
| JPMORGAN | Chris Schott |
| HSBC | |
| JEFFERIES | Akash Tewari |
| Jefferies & Co. | |
| UBS | |
| RBC Capital Markets | |
| BARCLAYS | Emily Field |
| Daiwa Securities | |
| Leerink Partners | |
| DZ BANK | Elmar Kraus |
| Citigroup | |
| Rothschild & Co Redburn | |
| CICC Research | |
| BMO Capital | |
| Guggenheim | |
| GOLDMAN SACHS | Asad Haider |
| Wolfe Research | |
| Cantor Fitzgerald | |
| BERENBERG | Luisa Hector |
| Morgan Stanley | |
| Scotiabank | |
| CMB International | |
| TD Cowen | |
| BERNSTEIN RESEARCH | Justin Smith |
| Berenberg Bank | |
| Redburn Atlantic | |
| Bernstein | |
| Wells Fargo Securities | |
| DA Davidson | |
| Argus | |
| Truist Securities | |
| Redburn | |
| SVB Securities LLC | |
| Credit Suisse | |
| Atlantic Equities | |
| Mizuho Securities | |
| Atlantic Securities | |
| SVB Leerink | |
| Independent Research | |
| J.P. Morgan Chase |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- PFE Stock
- Consensus Pfizer Inc.
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition